The Proteomics Shared Resource provides analytical proteomics services to investigators in the VICC. Proteomics is the study of proteomes, which are the functional complements to genomes and which comprise diverse structural and catalytically functional multiprotein machines. Proteomics approaches offer new tools for the molecular analysis of cancer, the identification of therapeutic targets and mechanisms, and to identify markers for disease and therapeutic response. Analytical proteomics integrates tools for protein and peptide separations, MS analysis and bioinformatics to characterize proteomes and their component proteins. A unique feature of the Proteomics Shared Resource is the availability of all major proteomics analysis technologies, which offers exceptional flexibility in analytical approaches. It provides the following services: identification of proteins in both simple and complex multiprotein samples; analyses of protein modifications; analyses of differential protein expression and modification; development and implementation of methods to detect serum markers for tumors, therapeutic susceptibility and response; providing expertise and training in proteomics analysis and experimental design to VICC investigators; and facilitating the transition of new technology into proteomics research. Dr. Daniel C. Liebler serves as Scientific Director. A recent recruit to the VICC, he previously established a successful Proteomics Shared Resource in the Southeast Environmental Health Sciences Center and Arizona Cancer Center at the University of Arizona. The staff of the Shared Resource have specialized expertise that enable them assist investigators with coverage of a vast number of new technologies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA068485-09
Application #
6990134
Study Section
Subcommittee G - Education (NCI)
Project Start
2004-09-28
Project End
2009-08-31
Budget Start
2004-09-28
Budget End
2005-08-31
Support Year
9
Fiscal Year
2004
Total Cost
$152,505
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Type
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Marks, Christian R; Shonesy, Brian C; Wang, Xiaohan et al. (2018) Activated CaMKII? Binds to the mGlu5 Metabotropic Glutamate Receptor and Modulates Calcium Mobilization. Mol Pharmacol 94:1352-1362
Singh, Kshipra; Coburn, Lori A; Asim, Mohammad et al. (2018) Ornithine Decarboxylase in Macrophages Exacerbates Colitis and Promotes Colitis-Associated Colon Carcinogenesis by Impairing M1 Immune Responses. Cancer Res 78:4303-4315
Pollins, Alonda C; Boyer, Richard B; Nussenbaum, Marlieke et al. (2018) Comparing Processed Nerve Allografts and Assessing Their Capacity to Retain and Release Nerve Growth Factor. Ann Plast Surg 81:198-202
Coppola, Jennifer J; Disney, Anita A (2018) Most calbindin-immunoreactive neurons, but few calretinin-immunoreactive neurons, express the m1 acetylcholine receptor in the middle temporal visual area of the macaque monkey. Brain Behav 8:e01071
Hull, P C; Buchowski, M; Canedo, J R et al. (2018) Childhood obesity prevention cluster randomized trial for Hispanic families: outcomes of the healthy families study. Pediatr Obes 13:686-696
Fensterheim, Benjamin A; Young, Jamey D; Luan, Liming et al. (2018) The TLR4 Agonist Monophosphoryl Lipid A Drives Broad Resistance to Infection via Dynamic Reprogramming of Macrophage Metabolism. J Immunol 200:3777-3789
Covington, Brett C; Spraggins, Jeffrey M; Ynigez-Gutierrez, Audrey E et al. (2018) Response of Hypogean Actinobacterial Genera Secondary Metabolism to Chemical and Biological Stimuli. Appl Environ Microbiol :
Hong, Jun; Maacha, Selma; Belkhiri, Abbes (2018) Transcriptional upregulation of c-MYC by AXL confers epirubicin resistance in esophageal adenocarcinoma. Mol Oncol 12:2191-2208
Dahlman, Kimberly Brown; Weinger, Matthew B; Lomis, Kimberly D et al. (2018) Integrating Foundational Sciences in a Clinical Context in the Post-Clerkship Curriculum. Med Sci Educ 28:145-154
Ramsey, Haley E; Fischer, Melissa A; Lee, Taekyu et al. (2018) A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia. Cancer Discov 8:1566-1581

Showing the most recent 10 out of 2462 publications